Ranolazine and late cardiac sodium current--a therapeutic target for angina, arrhythmia and more?

British Journal of Pharmacology
J C Makielski, Carmen R Valdivia

Abstract

Ranolazine is a new antianginal drug approved for clinical use in the United States in January 2006. A study published in this same issue of the British Journal of Pharmacology characterizes ranolazine block of late sodium current caused by the long QT syndrome 3 mutations. This commentary discusses the implications of that study and the background and implications for block of late cardiac sodium current in general.

References

Dec 1, 1990·The American Journal of Physiology·S E AndersonP M Cala
Dec 1, 1994·Journal of Cardiovascular Pharmacology·S C BlackB R Lucchesi
Aug 1, 1994·Cardiovascular Research·M R GralinskiB R Lucchesi
Jan 1, 1993·Circulation Research·C SteenbergenE Murphy
May 1, 1996·Circulation Research·R DumaineG E Kirsch
Apr 1, 1996·Journal of Molecular and Cellular Cardiology·G S ShanderJ C Makielski
Dec 1, 1996·The Journal of Physiology·Y K JuP W Gage
Apr 29, 1998·General Pharmacology·J G McCormackA A Wolff
May 6, 1999·Cellular and Molecular Life Sciences : CMLS·A I UndrovinasH N Sabbah
Jan 22, 2004·JAMA : the Journal of the American Medical Association·Bernard R ChaitmanUNKNOWN Combination Assessment of Ranolazine In Stable Angina (CARISA) Investigators
Mar 20, 2004·The Journal of Pharmacology and Experimental Therapeutics·Lin WuLuiz Belardinelli
Apr 20, 2004·Journal of the American College of Cardiology·Bernard R ChaitmanUNKNOWN MARISA Investigators
Jul 10, 2004·Journal of Cardiovascular Pharmacology·Yejia SongLuiz Belardinelli
Jul 28, 2004·British Journal of Pharmacology·Gernot SchramStanley Nattel
Mar 1, 2005·Journal of Molecular and Cellular Cardiology·Carmen R ValdiviaJonathan C Makielski
Mar 8, 2006·British Journal of Pharmacology·Sandra FredjRobert S Kass

❮ Previous
Next ❯

Citations

Sep 1, 2011·Nature Reviews. Cardiology·Bernard R Chaitman, Abhay A Laddu
Jul 6, 2006·Nature Reviews. Drug Discovery·Jonathan AbramsPeter Kirkpatrick
Jun 27, 2013·The Journal of Physiology·Zhuo FuZhenqi Liu
Mar 7, 2008·The Journal of Pharmacology and Experimental Therapeutics·Wei-Qun WangLuiz Belardinelli
May 12, 2007·International Journal of Clinical Practice·D Q Pham, M Mehta
Mar 31, 2007·International Journal of Clinical Practice·Graham Jackson
Apr 9, 2009·Progress in Biophysics and Molecular Biology·Jingjing WuMing Lei
Jun 12, 2009·Journal of Medicinal Chemistry·Bruno Le GrandBernard Vacher
May 28, 2008·Journal of Molecular and Cellular Cardiology·R S KassW J Lederer

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.